| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
IC50: Epstein-Barr virus
|
|---|---|
| ln Vitro |
The anti-tumor promoting activity of paederoside was evaluated using a short-term in vitro assay for inhibition of TPA-induced Epstein-Barr virus early antigen (EBV-EA) activation in Raji cells. At a concentration of 1000 mol ratio/TPA, paederoside showed 0 ± 0.1% of control (viability 30%). At 500 mol ratio/TPA, it showed 18.6 ± 1.9% of control (viability 60%). At 100 mol ratio/TPA, it showed 57.0 ± 1.5% of control (viability >80%). At 10 mol ratio/TPA, it showed 90.4 ± 0.3% of control (viability >80%). Among all iridoids tested, paederoside was found to be the most active, with slightly higher activity than genipin [1].
|
| Cell Assay |
The inhibition of Epstein-Barr virus early antigen (EBV-EA) induction was assayed using Raji cells (a human Burkitt's lymphoma cell line). Triplicate assays were performed. The EBV-EA inhibiting activity of paederoside was estimated based on the percentage of EBV-EA positive cells compared to that of a control (TPA alone, 32 pmol, 20 ng, set as 100%). Cell viability was also assessed simultaneously. The assay procedure followed that described previously (Honda et al., 1991). Briefly, Raji cells were incubated with TPA (32 pmol) and various concentrations of paederoside (at mol ratios of 1000, 500, 100, 10 relative to TPA). After incubation, the percentage of cells expressing EBV-EA was determined by staining with specific antibodies, and cell viability was measured using a trypan blue staining method [1].
|
| Toxicity/Toxicokinetics |
In the cell viability assay using Raji cells, paederoside at 1000 mol ratio/TPA reduced cell viability to 30%, indicating cytotoxic effects at this concentration. At 500 mol ratio/TPA, cell viability was 60%. At lower concentrations (100 and 10 mol ratio/TPA), cell viability remained above 80% [1]. Hydrolysis of paederoside in 6% aqueous barium hydroxide at room temperature for 18 hours produced methyl mercaptan (CH₃SH), which was identified as the mercury salt (CH₃S)₂Hg. This observation indicates that paederoside can release methyl mercaptan under alkaline hydrolytic conditions [2].
|
| References |
|
| Additional Infomation |
Paederoside is a glycoside. It has been reported to exist in Pseudomegoura nipponica, Paederia scandens, and other organisms with relevant data.
Paederoside was isolated from Paederia scandens and Paederia foetida (Rubiaceae). Its structure was revised from a thioacetate (2) to an S-methyl thiocarbonate (1) based on electron impact mass spectrometry (showing an aglucone molecular ion at m/z 284 instead of 268, and intense ions at m/z 47, 48, 75), chemical ionization mass spectrometry (showing aglucone+H⁺ at m/z 285 and (M+NH₄)⁺ at m/z 464 with ammonia CI), and hydrolysis products (methyl mercaptan instead of thioacetic acid). Paederoside is the first known naturally occurring S-methyl thiocarbonate. The unpleasant odor emitted by Paederia foetida is due to methyl mercaptan, which is likely formed from the crushed plant through enzymatic hydrolysis of paederoside [2]. |
| Molecular Formula |
C18H22O11S
|
|---|---|
| Molecular Weight |
446.4257
|
| Exact Mass |
446.088
|
| CAS # |
20547-45-9
|
| PubChem CID |
442432
|
| Appearance |
White to off-white solid
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
737.3±70.0 °C at 760 mmHg
|
| Melting Point |
122-123℃
|
| Flash Point |
399.7±35.7 °C
|
| Vapour Pressure |
0.0±5.5 mmHg at 25°C
|
| Index of Refraction |
1.661
|
| LogP |
-2.53
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
30
|
| Complexity |
767
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
S(C([H])([H])[H])C(=O)OC([H])([H])C1=C([H])[C@]2([H])[C@]3([H])C(=C([H])O[C@@]([H])([C@@]31[H])O[C@]1([H])[C@@]([H])([C@@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O1)O[H])O[H])O[H])C(=O)O2
|
| InChi Key |
OJISWUQNQQWEND-FCVLBCLDSA-N
|
| InChi Code |
InChI=1S/C18H22O11S/c1-30-18(24)26-4-6-2-8-11-7(15(23)27-8)5-25-16(10(6)11)29-17-14(22)13(21)12(20)9(3-19)28-17/h2,5,8-14,16-17,19-22H,3-4H2,1H3/t8-,9+,10+,11-,12+,13-,14+,16-,17-/m0/s1
|
| Chemical Name |
[(4S,7S,8S,11S)-2-oxo-8-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,9-dioxatricyclo[5.3.1.04,11]undeca-1(10),5-dien-6-yl]methyl methylsulfanylformate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~224.00 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.60 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2400 mL | 11.2000 mL | 22.3999 mL | |
| 5 mM | 0.4480 mL | 2.2400 mL | 4.4800 mL | |
| 10 mM | 0.2240 mL | 1.1200 mL | 2.2400 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
